Idexx Laboratories (IDXX) Cost of Revenue (2009 - 2026)

Idexx Laboratories (IDXX) has reported Cost of Revenue for 18 consecutive years, with $175.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue fell 53.27% year-over-year to $175.2 million; the TTM figure through Mar 2026 stood at $925.3 million (down 12.36% YoY), while the FY2025 annual figure was $643.5 million, up 9.35% from the prior year.
• Cost of Revenue came in at $175.2 million for Q1 2026 at Idexx Laboratories, up from $167.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $421.9 million in Q3 2025, with the low at -$529.5 million in Q4 2023.
• Average Cost of Revenue over 5 years is $176.2 million, with a median of $150.1 million recorded in 2024.
• Across the five-year window, Cost of Revenue jumped 191.11% in 2022 and sank 501.32% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $131.9 million in 2022, then tumbled by 501.32% to -$529.5 million in 2023, then jumped by 128.35% to $150.1 million in 2024, then increased by 11.29% to $167.1 million in 2025, then grew by 4.9% to $175.2 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $175.2 million, $167.1 million, and $421.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.